Calidi Biotherapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2022 | 50.4% | 50.4% | -979.1% |
| FY2023 | 354.8% | 473.1% | -291.6% |
| FY2024 | -1,443.5% | -1,037.6% | -156.1% |
| FY2025 | -529.6% | -456.7% | -224.7% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2022 | 50.4% | 50.4% | -979.1% |
| FY2023 | 354.8% | 473.1% | -291.6% |
| FY2024 | -1,443.5% | -1,037.6% | -156.1% |
| FY2025 | -529.6% | -456.7% | -224.7% |